ArticleResearch (Washington, D.C.)2026
Scoparone-Induced Phase Separation of ZDHHC12 Drives Ferroptosis via ATG12 S-palmitoylation and Ferritinophagy in Liver Fibrosis.
Article in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activated hepatic stellate cells (HSCs) are central effectors of liver fibrogenesis, and their selective elimination is critical for fibrosis regression. Although ferroptotic clearance of HSCs has emerged as a promising antifibrotic strategy, the upstream mechanisms coupling metabolic remodeling to ferroptosis susceptibility remain unclear. This study investigated whether scoparone (SCO) suppresses liver fibrosis through zinc finger DHHC-type palmitoyltransferase 12 (ZDHHC12) condensate formation, leading to enhanced autophagy-related protein 12 (ATG12) S-palmitoylation, induction of autophagy, and increased ferroptosis susceptibility in HSCs. We found that SCO restrained cell proliferation, migration, and fibrogenic activation while inducing iron overload, lipid peroxidation, glutathione depletion, and ferroptosis-like mitochondrial remodeling. Metabolomic and S-palmitoylation analyses linked these effects to increased palmitic acid levels and enhanced global protein S-palmitoylation. ZDHHC12 emerged as a SCO-responsive palmitoyltransferase associated with autophagy activation, ferritin turnover, ferroptosis induction, and repression of fibrogenic markers. Mechanistically, SCO promoted the formation of liquid-like ZDHHC12 condensates, which enhanced its interaction with ATG12 and facilitated ATG12 S-palmitoylation at the conserved Cys134 residue. This modification was associated with increased ATG12 stability through reduced ubiquitin-dependent proteasomal degradation, thereby promoting autophagy activation and increasing ferroptosis susceptibility in HSCs. Mutation of ATG12 at Cys134 attenuated these effects and diminished HSC ferroptosis. In cholestatic and toxic models of liver fibrosis, SCO alleviated liver injury and collagen deposition, whereas HSC-targeted silencing of ZDHHC12 or ATG12 attenuated these protective effects, supporting biological consistency in vivo. Integrated bioinformatic and clinical cohort analyses suggested that ZDHHC12 expression positively correlated with ATG12 expression and was associated with fibrosis progression in patients with liver fibrosis. Collectively, these findings support a ZDHHC12-dependent ATG12 S-palmitoylation pathway linking lipid metabolic remodeling to autophagy-mediated ferroptosis in HSCs and suggest phase-regulated S-palmitoylation as a potential antifibrotic target.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.